We are witnessing rapidly unfolding efforts to reinvigorate the antibacterial pipeline, improve antimicrobial stewardship and bring the multidrug microbial resistance under control. Industry, academia and government entities are working together on sustainable
solutions for the antibiotic resistance crisis. Multidrug-resistant Gram-negative bacteria currently pose the biggest threat and attract the most attention from researchers and policy makers. Novel platforms, screening strategies and new drugs as
well as new pathways for clinical development and market access are needed to overcome the current state of emergency associated with multidrug-resistant bacteria. Cambridge Healthtech Institute's 5th Annual Re-Entering Antibacterial Discovery and
Development Summit is designed as a knowledge and experience exchange for the major stakeholders working in this important area. The Summit features two conferences, Antibacterial Discovery and Development (September 26-27) and Targeting Gram-Negative
Pathogens (September 27-28), and several short courses.
Advisors: Lynn Silver, LL Silver Consulting; Ruben Tommasi, Entasis Therapeutics; Joyce Sutcliffe, Formerly Tetraphase; Todd Black, Merck